Christopher Sarchi
About Christopher Sarchi
Christopher Sarchi is Chief Commercial Officer at Replimune Group, Inc. (REPL). Age 55 as of July 16, 2025, he joined REPL in December 2022 after 32 years in pharma with 29 in oncology, and holds a B.S. in Business Administration from the University of Maine . He led Libtayo’s launch in cutaneous squamous cell carcinoma (CSCC) at Sanofi and was involved in Erivedge’s launch in basal cell carcinoma at Genentech, with nine oncology product launches/expansions across tumor types cited by the company . REPL’s proxy includes pay-versus-performance disclosures benchmarked to cumulative TSR and net loss at the company level, but executive-specific performance metrics for Sarchi are not provided .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Sanofi | Head of Oncology & Transplant, North America; later General Manager & Head, Oncology & Transplant | 2017–2019; 2019–2022 | Led Libtayo launch as new standard of care in CSCC |
| Boehringer Ingelheim | VP of Sales, Oncology; VP, Oncology Sales & Marketing | 2013–2017 | Senior commercial leadership across oncology sales and marketing |
| Genentech | Oncology Regional Sales Director | 2010–2013 | Involved with launch of Erivedge in BCC; co-promotion coordination of key franchises |
| Roche | Oncology Regional Sales Director | 2005–2010 | Regional commercial leadership in oncology |
| GlaxoSmithKline | Oncology Regional Sales Manager | 2002–2005 | Early oncology commercial leadership roles |
External Roles
- No external directorships or committee roles for Sarchi are disclosed in REPL’s proxies .
Fixed Compensation
- Not disclosed. Sarchi is not listed among Named Executive Officers (NEOs) in FY2024 or FY2025 Summary Compensation Tables; those tables cover CEO, CFO, and CMO only . Base salary tables likewise list CEO, CFO, CMO but not Sarchi .
Performance Compensation
- Not disclosed for Sarchi. The FY2024–FY2025 proxy narrative and tables detail cash bonus outcomes and equity awards for CEO/CFO/CMO, but do not include Sarchi .
Equity Ownership & Alignment
| Metric | As of Jun 30, 2025 |
|---|---|
| Direct/common shares owned | 27,877 |
| Options exercisable within 60 days | 95,192 |
| Total beneficial ownership (SEC definition) | 123,069 |
| Ownership as % of shares outstanding | <1% (“*” less than 1%) |
| Shares outstanding reference | 77,807,174 shares |
| Hedging/Pledging | Company policy prohibits hedging and pledging/margin holdings |
| Clawback | Compensation Recoupment Policy adopted Nov 20, 2023 |
- Beneficial ownership includes options vested/exercisable within 60 days, per SEC rules; no pledging is permitted under REPL’s insider trading policy .
Employment Terms
- Start date: Appointed Chief Commercial Officer effective immediately via press release Jan 4, 2023; company states he joined management in December 2022 .
- Employment agreement/severance terms: Not disclosed for Sarchi in proxies/8-Ks reviewed. REPL discloses agreements for other executives (e.g., CEO, CMO), but no specific contract terms for Sarchi appear in FY2024–FY2025 proxies .
- Company-wide policies: Clawback adopted Nov 20, 2023; anti-hedging/anti-pledging policy; equity grants typically approved with an April 1 grant date cycle and not timed to MNPI .
Investment Implications
- Alignment: Sarchi holds a modest equity stake (123,069 total beneficial shares; <1%), with 95,192 options exercisable within 60 days of June 30, 2025—indicating ongoing equity-based alignment but limited absolute exposure relative to the float . The prohibition of hedging/pledging and presence of a clawback policy reduce misalignment and governance risk .
- Retention risk: Lack of disclosed employment/severance terms and change-of-control economics for Sarchi limits visibility on retention incentives versus downside protection. Contrast with detailed CEO/CMO agreements to gauge relative leverage and potential transition risk at the commercial function .
- Trading signals: With options currently exercisable counted in beneficial ownership and strong anti-hedging/pledging policies, near-term insider selling pressure would primarily depend on Form 4 activity rather than policy-driven liquidity. No Form 4 details are provided in the reviewed documents; monitor filings for exercise/sales cadence .
- Pay-for-performance visibility: Compensation metric targeting (e.g., revenue, TSR, clinical/regulatory milestones) for Sarchi is not disclosed, limiting granular pay-for-performance analysis. Company-level pay-versus-performance exhibits exist but are not executive-specific for Sarchi; focus on revenue/launch readiness outcomes for RPx programs as practical performance proxies .